Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Upper tract urothelial carcinoma is non-basal and T-cell depleted

Funder: Bladder Cancer Advocacy Network

Funding period
USD 2 K
Funding amount
Abstract
Urothelial cancer (UC) of the upper urinary tract (UTUC) accounts for 5-10% of UC.Despite sharing a common histology with bladder UC (UCB),staging & prognosis differences have been reported.To dissect the central biological features of UTUC driving its phenotype,we performed an integrated analysis of UTUC tumors using whole-exome (WES) & RNA sequencing (RNAseq).We compared the exome & transcriptome of UTUC to the TCGA UCB and an independent UTUC validation dataset (VALD).We performed an integrated analysis of WES (n=16) & RNAseq (n=19) from biobanked nephroureterectomy archival specimens of 19 chemotherapy-naïve patients with UTUC. Patients’ demographics are as follows:median age 71 (range 46-87);11 men,8 women;11 former/current smokers;13 renal pelvis,6 ureteral;17 high-grade,2 low-grade;8 low stage (=pT2).Our analyses revealed several insights:1) UTUC has a significantly lower frequency of TP53 mutations (3/16, 18.7%) compared to UCB patients (198/412, 48%) (p=0.03) but similar frequency of mutations in chromatin modifying (KMT2C, KMT2D, KDM6A), transcription activation (CREBBP), receptor tyrosine kinase (FGFR3, PIK3CA, ERBB2, KRAS), & cell cycle regulation (RB1) genes.2) UTUC is characterized by downregulation of the DNA mismatch repair genes (p=0.05) & APOBEC3A, APOBEC3B genes (p<0.01) & a lower total mutational burden compared to UCB (2 vs 5 mutations per Mb, p=0.01).3) UTUC is intrinsically non-basal. UTUC is predominantly luminal by UNC (18/19, 95%) & the MD Anderson (MDA) (17/19, 89%) criteria, and luminal-papillary (16/19, 84%) by the TCGA criteria. All VALD UTUC tumors (n=10) clustered with the luminal-papillary subtype.4) UTUC tumors exhibit a T-cell depleted phenotype (17/19, 89%). 5) FGFR3 expression is a dominant transcriptional outlier in UTUC (7/19, 37%) and is associated with T-cell depleted phenotype (p<0.01).By dissecting the biology of UTUC,we provide the biological rationale for future UTUC-specific therapeutic strategies.
Similar projects All >
Sorted by: Start Date
Project list item
Next generation sequencing to enhance initial staging and dynamically monitor disease response in upper tract urothelial carcinoma

Bladder Cancer Advocacy Network to Philip Hilmi Abbosh, Wafik El-Deiry, Elizabeth Plimack

USD 50,000
2018 - 2019
Project list item
Ascertaining the role of mutations in COMPASS-like complex members in the development of upper tract urothelial carcinoma

Bladder Cancer Advocacy Network to Byron H Lee, Nima Sharifi, Ming Hu, Daniel Kim

USD 50,000
2017 - 2018
Project list item
The likelihood of underlying Lynch syndrome in upper tract urothelial carcinoma patients

Japan Society for the Promotion of Science to Masaya ITO

USD 21,145
2016 - 2018
Project list item
Epithelial to mesenchymal transition thorough GEP100-Arf6-AMAP1 pathway in urothelial cancer

Japan Society for the Promotion of Science to Tatsuaki Daimon

USD 34,348
2015 - 2017
Project list item
Investigation of anti-tumor effect of Axl kinase inhibitor in urothelial carcinoma.

Japan Society for the Promotion of Science to Seiya Hattori

USD 33,260
2014 - 2016

System

Categories
  • FOR (ANZSRC)

    0604 Genetics

  • RCDC

    Human Genome

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical